Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pediatric Study Compliance Could Face Scrutiny In PDUFA Renewal

Executive Summary

FDA says compliance is on par with other postmarketing requirements, but jury is still out on whether public posting of noncompliance letters has been effective tool to ensure timely trial completion.

Advertisement

Related Content

PDUFA VI: Pediatrics Group Seeks Earlier And Faster Studies
Opioid Studies In Children Still Facing Design Challenges
Opioid Studies In Children Still Facing Design Challenges
Industry Ranks Well On Pediatric Trial Completion But Not Publication
Pediatric Study Requirements For Cancer Have FDA Support, But Pose Industry Challenges
FDA Postmarketing Study Oversight To Benefit From Informatics Upgrades
Pediatric Studies Delayed Mostly By FDA Red Tape, Companies Say

Topics

Advertisement
UsernamePublicRestriction

Register

PS118940

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel